Atrial Fibrillation and Heart Failure: Update 2015

Progress in Cardiovascular Diseases

Volumn 58, Issue 2, 2015, Pages 126-135

  Thihalolipavan, Sudarone ^a   Morin, Daniel P ^a,b  

^a OCHSNER MEDICAL CENTER   (United States)

^b OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Anti arrhythmia drugs; Anticoagulation; Atrial fibrillation; Catheter ablation; Heart failure

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIVITAMIN K; APIXABAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DABIGATRAN; DOFETILIDE; DRONEDARONE; EDOXABAN; ENALAPRIL; OLMESARTAN; RIVAROXABAN; VALSARTAN; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; CARDIAC RESYNCHRONIZATION THERAPY; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CRYOABLATION; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; EPIDEMIOLOGICAL DATA; HEART ATRIOVENTRICULAR NODE; HEART FAILURE; HEART RATE; HUMAN; PATHOPHYSIOLOGY; PATIENT SAFETY; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM; ADVERSE EFFECTS; COMORBIDITY; MORTALITY; PATIENT SELECTION; QUALITY OF LIFE; TREATMENT OUTCOME;

ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIAC RESYNCHRONIZATION THERAPY; CATHETER ABLATION; COMORBIDITY; HEART FAILURE; HUMANS; PATIENT SELECTION; QUALITY OF LIFE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84942195131     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2015.07.004     Document Type: Article

References (124)

1. Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults; national implications for rhythm management and stroke prevention: the Anticoagulation and risk factors in Atrial Fibrillation study (ATRIA). J Am Med Assoc 2001, 285:2370-2375.
2. Roger V.L., Go A.S., Lloyd-Jones D.M., et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012, 125(1):e2-e220.
3. Kim M.H., Johnston S.S., Chu B.C., et al. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes 2011, 4(3):313-320.
4. Fuster V., Ryden L.E., Asinger R.W., et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. Circulation 2001, 104:2118-2150.
5. Heidenriech P.A., Trogdon J.G., Khavjou O.A., et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011, 123(8):933-944.
6. Dries D.L., Exner D.V., Gersh B.J., Domanski M.J., Waclawiw M.A., Stevenson L.W. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction a retrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998, 32:695-703.
7. Mountantonakis S.E., Grau-Sepulveda M.V., Bhatt D.L., Hernandez A.F., Peterson E.D., Fonarow G.C. Presence of atrial fibrillation is independently associated with adverse outcomes in patients hospitalized with heart failure: an analysis of Get With the Guidelines-Heart Failure. Circ Heart Fail 2012, 5(2):191-201.
8. Mamas M.A., Caldwell J.C., Chako S., Garratt C.J., Fath-Ordoubadi F., Neyses L. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail 2009, 11:676-683.
9. Chamberlain A.M., Redfield M.M., Alonso A., Weston S.A., Roger V.L. Atrial fibrillation and mortality in heart failure: a community study. Circ Heart Fail 2011, 4:740-746.
10. Wasywich C.A., Pope A.J., Somartne J., Poppe K.K., Whalley G.A., Doughty R.N. Atrial fibrillation and the risk of death in patients with heart failure: a literature-based meta-analysis. Intern Med J 2010, 40:347-356.
11. Khazanie P., Liang L., Qualls L.G., et al. Outcomes of medicare beneficiaries with heart failure and atrial fibrillation. JCHF 2014, 2(1):41-48.
12. Wang T.J., Larson M.G., Levy D., et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003, 107:2920-2925.
13. Stevenson W.G., Stevenson L.W., Middlekauff H.R., et al. Improving survival for patients with atrial fibrillation and advanced heart failure. J Am Coll Cardiol 1996, 28:1458-1463.
14. Carson P.E., Johnson G.R., Dunkman W.B., et al. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation 1993, 87:V102-V110.
15. Maisel W.H., Stevenson L.W. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003, 91:2D-8D.
16. Mentz R.J., Chung M.J., Gheorghiade M., et al. Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial. Am Heart J 2012, 164:884-892.
17. Lubitz S.A., Benjamin E.J., Ellinor P.T. Atrial fibrillation in congestive heart failure. Heart Fail Clin 2010, 6(2):187-200.
18. Anter E., Jessup M., David J., Callans D.J. Atrial fibrillation and heart failure treatment considerations for a dual epidemic. Circulation 2009, 119:2516-2525.
19. Smit M.D., Moes M.L., Maass A.H., et al. The importance of whether atrial fibrillation or heart failure develops first. Eur J Heart Fail 2012, 14(9):1030-1040.
20. Verheule S., Wilson E., Everett T.T., Shanbhag S., Golden C., Olgin J. Alterations in atrial electrophysiology and tissue structure in a canine model of chronic atrial dilatation due to mitral regurgitation. Circulation 2003, 107:2615-2622.
21. Li D., Melnyk P., Feng J., et al. Effects of experimental heart failure on atrial cellular and ionic Electrophysiology. Circulation 2000, 101:2631-2638.
22. Li D., Fareh S., Leung T.K., Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 1999, 100:87-95.
23. Boyden P.A., Tilley L.P., Pham T.D., Liu S.K., Fenoglio J.J., Wit A.L. Effects of left atrial enlargement on atrial transmembrane potentials and structure in dogs with mitral valve fibrosis. Am J Cardiol 1982, 49:1896-1908.
24. Boyden P.A., Tilley L.P., Albala A., Liu S.K., Fenoglio J.J., Wit A.L. Mechanisms for atrial arrhythmias associated with cardiomyopathy: a study of feline hearts with primary myocardial disease. Circulation 1984, 69:1036-1047.
25. Sanders P., Morton J.B., Davidson N.C., et al. Electrical remodeling of the atria in congestive heart failure: electrophysiological and electrophysiological and electroanatomic mapping in humans. Circulation 2003, 108:1461-1468.
26. Ohtani K., Yutani C., Nagata S., et al. High prevalence of atrial fibrosis in patients with dilated cardiomyopathy. J Am Coll Cardiol 1995, 25:1162-1169.
27. Everett T.H., Olgin J.E. Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm 2007, 4:S24-S27.
28. Boos C.J., Anderson R.A., Lip G.Y. Is atrial fibrillation an inflammatory disorder?. Eur Heart J 2006, 27:136-149.
29. Boo C.J., Lip G.Y. Inflammation and atrial fibrillation: cause or effect?. Heart 2008, 94:133-134.
30. Reil J.C., Hohl M., Selejan S., et al. Aldosterone promotes atrial fibrillation. Eur Heart J 2012, 33:2098-2108.
31. Gossage A.M., Braxton Hicks J.A. On auricular fibrillation. QJM 1913, 6:435-440.
32. Philips E., Levine S.A. Auricular fibrillation without other evidence of heart disease: a cause of reversible heart failure. Am J Med 1949, 7:479-489.
33. Whipple G.H., Sheffield L.T., Woodman E.G., et al. Reversible congestive heart failure due to chronic rapid stimulation of the normal heart. Proc N Engl Cardiovasc Soc 1962, 20:39-40.
34. Wang T.J., Larson M.G., Levy D., et al. Temporal relation of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003, 107(23):2920-2925.
35. Thygesen S.K., Frost L., Eagle K.A., Johnsen S.P. Atrial fibrillation in patients with ischemic stroke: a population-based study. Clin Epidemiol 2009, 1:55-65.
36. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991, 22(8):983-988.
37. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994, 154:1449-1457.
38. Stroke Prevention in Atrial Fibrillation Investigators Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Study. J Stroke Cerebrovasc Dis 1995, 5:147-157.
39. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994, 343:687-691.
40. Stroke Prevention in Atrial Fibrillation Study Final results. Circulation 1991, 84:527-539.
41. Arnow W.S., Ahn C., Kronzon I., et al. Risk factors for new thromboembolic stroke in patient > or equal to 62years of age with chronic atrial fibrillation. Am J Cardiol 1998, 82:119-121.
42. Ezekowitz M.D., Laupacis A., Boysen G., et al. Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch Intern Med 1998, 158:1316-1320.
43. Pearce L.A. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. Arch Intern Med 1992, 116:6-12.
44. Van Walraven C., Hart R.G., Singer D.E., et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002, 288(19):2441-2448.
45. Gage B.F., Van Walraven C., Pearce L., et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004, 110(16):2287-2292.
46. Gage B.F., Waterman A.D., Shannon W., Boechler M., Rich M.W., Radford M.J. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285(22):2864-2870.
47. Lip G.Y., Nieuwlaat R., Pisters R., Lane D.A., Crijns H.J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 2010, 137(2):263-272.
48. January C. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol 2014, 64(21):2246-2280.
49. Olesen J.B., Lip G.Y., Hansen M.L., et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011, 342:d124-d133.
50. Lee B.H., Park J.S., Park J.H., et al. The effect and safety of the anti-thrombotic therapies in patients with atrial fibrillation and CHADS2 score 1. J Cardiovasc Electrophysiol 2010, 21(5):501-507.
51. Gorin L., Fauchier L., Nonin, et al. Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1. Thromb Haemost 2010, 103:833-840.
52. Connolly S., Pogue J., Hart R., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet 2006, 367:1903-1912.
53. Sato H., Ishikawa K., Kitabatake A., et al. Japan Atrial Fibrillation Stroke Trial Group. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke 2006, 37(2):447-451.
54. Lip G.Y. Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at 'moderate risk' [CHADS2 score=1]: simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice. Thromb Haemost 2010, 103(4):683-685.
55. Pisters R., Lane D.A., Nieuwlaat R., de Vos C.B., Crijns H.J., Lip G.Y. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010, 138(5):1093-1100.
56. Olsson L.G., Swedberg K., Ducharme A., et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 2006, 47(10):1997-2004.
57. Banerjee A., Taillandier S., Olesen J.B., et al. Ejection fraction and outcomes in patients with atrial fibrillation and heart failure 2012.
58. Jang S.J., Kim M.S., Park H.J., et al. Impact of heart failure with normal ejection fraction on the occurrence of ischaemic stroke in patients with atrial fibrillation. Heart 2013, 99(1):17-21.
59. Boos C., Nam M., Camm A.J. Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure. Heart Fail Rev 2014, 19:391-401.
60. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
61. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891.
62. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992.
63. Robert P., Giugliano M.D., ENGAGE AF-TIMI 48 Investigators Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013, 369:2093-2104.
64. McMurray J.J., Ezekowitz J.A., Lewis B.S., et al. Left ventricular systolic dysfunction, heart failure and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. Circ Heart Fail 2013, 6(3):451-460.
65. White H.D., Gruber M., Feyzi J., et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007, 167(3):239-245.
66. Connolly S.J., Pogue J., Eikelboom J., et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008, 118:2029-2037.
67. Apostolakis S., Sullivan R.M., Olshansky B., Lip G.Y. Factors affecting quality of anticoagulation control amongst atrial fibrillation patients on warfarin: the SAME-TT2R2 (sex female, age less than 60, medical history, treatment strategy (rhythm control), tobacco use (doubled), race (doubled) score. Chest 2013, 144:1555-1563.
68. Lamberts M., Lip G.Y., Ruwald M.H., et al. Antithrombotic treatment in patients with heart failure and associated atrial fibrillation and vascular disease: a nationwide cohort study. J Am Coll Cardiol 2014, 63(24):2689-2698.
69. Van Gelder I.C., Hagens V.E., Bosker H.A., et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002, 347:1834-1840.
70. Roy D., Talajic M., Nattel S., et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008, 358:2667-2677.
71. Trulock K., Narayan S., Piccini J.P. Rhythm control in heart failure patients with atrial fibrillation contemporary challenges including the role of ablation. JACC 2014, 64(7).
72. Corley S.D., Epstein A.E., DiMarco J.P., et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004, 109:1509-1513.
73. Talajic M., Khairy P., Levesque S., et al. Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. AF-CHF Investigators. J Am Coll Cardiol 2010, 55(17):1796-1802.
74. Opolski G., Torbicki A., Kosior D.A., et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 2004, 126:476-486.
75. Carlsson J., Miketic S., Windeler J., et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003, 41:1690-1696.
76. Van Gelder I.C., Hagens V.E., Kingma J.H., et al. Crijns HJGM Rate control versus electrical cardioversion for atrial fibrillation. A randomised comparison of two treatment strategies concerning morbidity, mortality, quality of life and cost-benefit-the RACE study design. Neth Heart J 2002, 10(3):118-122. [123-124].
77. Shelton R.J., Clark A.L., Goode K., et al. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFÉ-II Study). Heart 2009, 95:924-930.
78. Roy D., Talajic M., Dorian P., et al. Canadian Trial of Atrial Fibrillation Investigators. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 2000, 342:913-920.
79. Freemantle N., Lafuente-Lafuente C., Mitchell S., et al. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace 2011, 13:329-345.
80. Singh S., Zoble R.G., Yellen L., et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study. Circulation 2000, 102:2385-2390.
81. Pedersen O.D., Bagger H., Keller N., et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (DIAMOND) sub-study. Circulation 2001, 104:292-296.
82. Køber L., Torp-Pedersen C., McMurray J.J., et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008, 358:2678-2687.
83. Morrow D.A., Scirica B.M., Karwatowska-Prokopczuk E., et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 r andomized trial. JAMA 2007, 297(16):1775-1783.
84. Blomström-Lundqvist C., Blomström P. Safety and efficacy of pharmacological cardioversion of atrial fibrillation using intravenous vernakalant, a new antiarrhythmic drug with atrial selectivity. Expert Opin Drug Saf 2012, 11(4):671-679.
85. Koskinas K., Fragakis N., Katritsis D., Skeberis V., Vassilikos V. Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation. Europace 2014, 16:973-979.
86. Ezekowitz M.D., Nagarakanti R., Lubinski A., et al. A randomized trial of budiodarone in paroxysmal atrial fibrillation. J Interv Cardiac Electrophysiol 2012, 34:1-9.
87. Li D., Shinagawa K., Pang L., et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001, 104:2608-2614.
88. Vermes E., Tardif J.C., Bourassa M.G., et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003, 107:2926-2931.
89. Pedersen O.D., Bagger H., Kober L., et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999, 100:376-380.
90. Ducharme A., Swedberg K., Pfeffer M.A., et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006, 152:86-89.
91. Maggioni A.P., Latini R., Carson P.E., et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005, 149:548-557.
92. Goette A., Schon N., Kirchhof P., et al. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol 2012, 5:43-51.
93. The CAPRICORN Investigators Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001, 357:1385-1390.
94. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651-1658.
95. Waagstein F., Bristow M.R., Swedberg K., et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993, 342:1441-1446.
96. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001-2007.
97. Kotecha D. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 2014, 384:2235-2243. the Investigators of Beta-Blockers in Heart Failure Collaborative Group.
98. Rienstra M., Damman K., Mulder B.A., Van Gelder IC McMurray J.J., Van Veldhuisen D. Beta-blockers and outcome in heart failure and atrial fibrillation. JACC Heart Fail 2013, 1(1).
99. Nasr I.A., Bouzamondo A., Hulot J.S., et al. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J 2007, 28:457-462.
100. Swedberg K., Zannad F., McMurray J.J., et al. Eplerenone and atrial fibrillation in mild systolic: results from the EMPHAISIS-HF study. J Am Coll Cardiol 2012, 59(18):1598-1603.
101. Anderson Jeffrey L., Halperin Jonathan L., Albert Nancy M., et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations). A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013, 127:1916-1926.
102. Parkash R., Tang A.S., Sapp J.L., et al. Approach to the catheter ablation technique of paroxysmal and persistent atrial fibrillation: a meta-analysis of the randomized controlled trials. J Cardiovasc Electrophysiol 2011, 22:729-738.
103. Piccini J.P., Lopes R.D., Kong M.H., et al. Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a meta- analysis of randomized, controlled trials. Circ Arrhythm Electrophysiol 2009, 2:626-633.
104. Marrouche N.F., Brachmann J., CASTLE-AF Steering Committee Catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation (CASTLE-AF) study design. Pacing Clin Electrophysiol 2009, 32(8):987-994.
105. Cosedis Nielsen J., Johannessen A., Raatikainen P., et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med 2012, 367(17):1587-1595.
106. Morillo C.A., Verma A., Connolly S.J., et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA 2014, 311:692-700.
107. Chen M.S., Marrouche N.F., Khaykin Y., et al. Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function. J Am Coll Cardiol 2004, 43:1004-1009.
108. Hsu L.F., Jais P., Sanders P., et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004, 351:2373-2383.
109. Tondo C., Mantica M., Russo G., et al. Pulmonary vein vestibule ablation for the control of atrial fibrillation in patients with impaired left ventricular function. Pacing Clin Electrophysiol 2006, 29:962-970.
110. Gentlesk P.J., Sauer W.H., Gerstenfeld E.P., et al. Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2007, 18:9-14.
111. Jones D.G., Haldar S.K., Hussain W., et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol 2013, 61(18):1894-1903.
112. Hunter R.J., Berriman T.J., Diab I., et al. A randomised controlled trial of Catheter Ablation versus Medical Treatment of Atrial Fibrillation in Heart Failure (the CAMTAF trial). Circ Arrhythm Electrophysiol 2014, 7:31-38.
113. Wilton S.B., Fundytus A., Ghali W.A., et al. Meta-analysis of the effectiveness and safety of catheter ablation of atrial fibrillation in patients with versus without left ventricular systolic dysfunction. Am J Cardiol 2010, 106(9):1284-1291.
114. Manolis A.G., Katsivas A.G., Lazaris E.E., et al. Ventricular performance and quality of life in patients who underwent radiofrequency AV junction ablation and permanent pacemaker implantation due to medically refractory atrial tachyarrhythmias. J Interv Card Electrophysiol 1998, 2:71-76.
115. Kamath G.S., Cotiga D., Koneru J.N., et al. The utility of 12-lead Holter monitoring in patients with permanent atrial fibrillation for the identification of nonresponders after cardiac resynchronization therapy. J Am Coll Cardiol 2009, 53:1050-1055.
116. Gasparini M., Galimberti P. AV junction ablation in heart failure patients with atrial fibrillation treated with cardiac resynchronization therapy: the picture is now clear!. J Am Coll Cardiol 2012, 59(8):727-729.
117. Ganesan A.N., Brooks A.G., Roberts-Thomson K.C., Lau D.H., Kalman J.M., Sanders P. Role of AV nodal ablation in cardiac resynchronization in patients with coexistent atrial fibrillation and heart failure a systematic review. J Am Coll Cardiol 2012, 59(8):719-726.
118. Khan M.N., Jaïs P., Cummings J., et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 2008, 359:1778-1785.
119. Hsieh M.H., Tai C.T., Lee S.H., et al. Catheter ablation of atrial fibrillation versus atrioventricular junction ablation plus pacing therapy for elderly patients with medically refractory paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 2005, 16:457-461.
120. Cox J.L., Schuessler R.B., Lappas D.G., Boineau J.P. An 8 1/2-year clinical experience with surgery for atrial fibrillation. Ann Surg 1996, 224:267-273.
121. Lee A. The surgical treatment of atrial fibrillation. Surg Clin N Am 2009, 89(4):1001-1020. [x-xi].
122. Calkins H., Brugada J., Packer D.L., et al. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2007, 4(6):816-861.
123. Gersak B., Zembala M.O., Muller D., et al. European experience of the convergent atrial fibrillation procedure: multicenter outcomes in consecutive patients. J Thorac Cardiovasc Surg 2014, 147:1411-1416.
124. Gehi A.K., Mounsey J.P., Pursell I., et al. Hybrid epicardial-endocardial ablation using a pericardioscopic technique for the treatment of atrial fibrillation. Heart Rhythm 2013, 10:22-28.